Naga Vara Kishore Pillarsetty: Publications

The Naga Vara Kishore Pillarsetty Lab
Publications
Open Positions

Naga Vara Kishore Pillarsetty: Publications

Share
Share

View a full listing of Naga Vara Kishore Pillarsetty: Publications’ journal articles.

Zanoni DK, Demetrio De Souza Franca P, Valero C, Peterson G, Ardigo M, Ghossein R, Dusza SW, Matsuura D, Scholfield DW, Adilbay D, Montero PH, Migliacci J, Pillarsetty NVK, Kose K, Ganly I, Rajadhyaksha M, Patel SG. A Prospective Double-Blinded Comparison of Reflectance Confocal Microscopy with Conventional Histopathology for In Vivo Assessment in Oral Cancer. Clin Cancer Res. 2024;30(11):2486-96. doi: 10.1158/1078-0432.CCR-23-1361. PubMed PMCID: PMC11145174;

Imberti C, De Gregorio R, Korsen JA, Hoang TT, Khitrov S, Kalidindi T, Nandakumar S, Park J, Zaidi S, Pillarsetty NVK, Lewis JS. CEACAM5-Targeted Immuno-PET in Androgen Receptor-Negative Prostate Cancer. J Nucl Med. 2024. Epub 20240523. doi: 10.2967/jnumed.123.267107. PubMed

Gonzales J, Adilbay D, de Souza Franca PD, Artschwager R, Chow CY, Viray T, Johnson DS, Jiang Y, Patel SG, Ganly I, Schroeder CI, Lewis JS, King GF, Reiner T, Pillarsetty N. Na(V)1.7 targeted fluorescence imaging agents for nerve identification during intraoperative procedures. bioRxiv. 2024. Epub 20240406. doi: 10.1101/2024.04.06.588368. PubMed PMCID: PMC11014580;

Wilson TC, Jannetti SA, Guru N, Pillarsetty N, Reiner T, Pirovano G. Improved radiosynthesis of (123)I-MAPi, an auger theranostic agent. Int J Radiat Biol. 2023;99(1):70-6. Epub 20200702. doi: 10.1080/09553002.2020.1781283. PubMed PMCID: PMC7775866;

Sharma S, Joshi S, Kalidindi T, Digwal CS, Panchal P, Lee SG, Zanzonico P, Pillarsetty N, Chiosis G. Unraveling the Mechanism of Epichaperome Modulation by Zelavespib: Biochemical Insights on Target Occupancy and Extended Residence Time at the Site of Action. Biomedicines. 2023;11(10). Epub 20230922. doi: 10.3390/biomedicines11102599. PubMed PMCID: PMC10604720;

Pratt EC, Lopez-Montes A, Volpe A, Crowley MJ, Carter LM, Mittal V, Pillarsetty N, Ponomarev V, Udias JM, Grimm J, Herraiz JL. Simultaneous quantitative imaging of two PET radiotracers via the detection of positron-electron annihilation and prompt gamma emissions. Nat Biomed Eng. 2023;7(8):1028-39. Epub 20230703. doi: 10.1038/s41551-023-01060-y. PubMed PMCID: PMC10810307;

Periche PG, Lin J, Bhupathiraju N, Kalidindi T, Johnson DS, Pillarsetty N, Mootoo DR. Targeting Carbohydrate Mimetics of Tetrahydrofuran-Containing Acetogenins to Prostate Cancer. Molecules. 2023;28(7). Epub 20230323. doi: 10.3390/molecules28072884. PubMed PMCID: PMC10095889;

Mc Larney BE, Kim M, Roberts S, Skubal M, Hsu HT, Ogirala A, Pratt EC, Pillarsetty NVK, Heller DA, Lewis JS, Grimm J. Ambient Light Resistant Shortwave Infrared Fluorescence Imaging for Preclinical Tumor Delineation via the pH Low-Insertion Peptide Conjugated to Indocyanine Green. J Nucl Med. 2023;64(10):1647-53. Epub 20230824. doi: 10.2967/jnumed.123.265686. PubMed PMCID; PMC10586478;

Martinez J, Subramanian K, Castellanos SH, Thomas C, Choudhury AR, Muench B, Tagawa ST, Pillarsetty NVK, Osborne JR. Cyclotron vs generator-produced 68Ga PSMA: a single-institution, prospective clinical trial. Transl Oncol. 2023;28:101593. Epub 20221224. doi: 10.1016/j.tranon.2022.101593. PubMed PMCID: PMC9803810;

Demetrio de Souza Franca P, Viray T, Roberts S, Michel A, Abrahao M, Patel SG, Ganly I, Schoder H, Brand C, Reiner T, Pillarsetty NVK. Polyethylene Glycol 3350 (PEG 3350) as a Practical Vehicle for Rapid Reconstitution of PARPi-FL Formulations for Clinical Use. Mol Imaging Biol. 2023;25(2):294-302. Epub 20220726. doi: 10.1007/s11307-022-01756-8. PubMed

Bakht MK, Yamada Y, Ku SY, Venkadakrishnan VB, Korsen JA, Kalidindi TM, Mizuno K, Ahn SH, Seo JH, Garcia MM, Khani F, Elemento O, Long HW, Chaglassian A, Pillarsetty N, Lewis JS, Freedman M, Belanger AP, Nguyen QD, Beltran H. Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer. Nat Cancer. 2023;4(5):699-715. Epub 20230410. doi: 10.1038/s43018-023-00539-6. PubMed PMCID: PMC10867901;

Tully KM, Tendler S, Carter LM, Sharma SK, Samuels ZV, Mandleywala K, Korsen JA, Delos Reyes AM, Piersigilli A, Travis WD, Sen T, Pillarsetty N, Poirier JT, Rudin CM, Lewis JS. Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer Exhibits Antitumor Efficacy with Low Toxicity. Clin Cancer Res. 2022;28(7):1391-401. doi: 10.1158/1078-0432.CCR-21-1533. PubMed PMCID: PMC8976830;

Sharma S, Kalidindi T, Joshi S, Digwal CS, Panchal P, Burnazi E, Lee SG, Pillarsetty N, Chiosis G. Synthesis of (124)I-labeled epichaperome probes and assessment in visualizing pathologic protein-protein interaction networks in tumor bearing mice. STAR Protoc. 2022;3(2):101318. Epub 20220419. doi: 10.1016/j.xpro.2022.101318. PubMed PMCID: PMC9046997;

Saha N, Xu K, Zhu Z, Robev D, Kalidindi T, Xu Y, Himanen J, de Stanchina E, Pillarsetty NVK, Dimitrov DS, Nikolov DB. Inhibitory monoclonal antibody targeting ADAM17 expressed on cancer cells. Transl Oncol. 2022;15(1):101265. Epub 20211109. doi: 10.1016/j.tranon.2021.101265. PubMed PMCID: PMC8592942;

Russell J, Fanchon L, Alwaseem H, Molina H, O’Donoghue I, Bahr A, de Stanchina E, Pillarsetty N, Humm JL. Analysis of capecitabine metabolites in conjunction with digital autoradiography in a murine model of pancreatic cancer suggests extensive drug penetration through the tumor. Pharmacol Res Perspect. 2022;10(2):e00898. doi: 10.1002/prp2.898. PubMed PMCID: PMC8902142;

Nagle VL, Hertz CAJ, Henry KE, Graham MS, Campos C, Pillarsetty N, Schietinger A, Mellinghoff IK, Lewis JS. Noninvasive Imaging of CD4+ T Cells in Humanized Mice. Mol Cancer Ther. 2022;21(4):658-66. doi: 10.1158/1535-7163.MCT-21-0888. PubMed PMCID: PMC8983497;

Korsen JA, Kalidindi TM, Khitrov S, Samuels ZV, Chakraborty G, Gutierrez JA, Poirier JT, Rudin CM, Chen Y, Morris MJ, Pillarsetty N, Lewis JS. Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3. J Nucl Med. 2022;63(9):1401-7. Epub 20220120. doi: 10.2967/jnumed.121.263221. PubMed PMCID: PMC9454466;

Korsen JA, Gutierrez JA, Tully KM, Carter LM, Samuels ZV, Khitrov S, Poirier JT, Rudin CM, Chen Y, Morris MJ, Bodei L, Pillarsetty N, Lewis JS. Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer. Proc Natl Acad Sci U S A. 2022;119(27):e2203820119. Epub 20220627. doi: 10.1073/pnas.2203820119. PubMed PMCID: PMC9271187;

Gonzalez Periche P, Ramdular A, Bhupathiraju N, Kalidindi T, Johnson DS, Pillarsetty N, Mootoo DR. Synthesis of carbohydrate analogues of the THF-acetogenin 4-deoxyannomontacin and their cytotoxicity against human prostate cancer cell lines. Carbohydr Res. 2022;521:108671. Epub 20220907. doi: 10.1016/j.carres.2022.108671. PubMed PMCID: PMC10288172;

Chakraborty G, Nandakumar S, Hirani R, Nguyen B, Stopsack KH, Kreitzer C, Rajanala SH, Ghale R, Mazzu YZ, Pillarsetty NVK, Lee GM, Scher HI, Morris MJ, Traina T, Razavi P, Abida W, Durack JC, Solomon SB, Vander Heiden MG, Mucci LA, Wibmer AG, Schultz N, Kantoff PW. The Impact of PIK3R1 Mutations and Insulin-PI3K-Glycolytic Pathway Regulation in Prostate Cancer. Clin Cancer Res. 2022;28(16):3603-17. doi: 10.1158/1078-0432.CCR-21-4272. PubMed PMCID: PMC9438279;

Adilbay D, Gonzales J, Zazhytska M, Demetrio de Souza Franca P, Roberts S, Viray T, Artschwager R, Patel S, Kodra A, Overdevest JB, Chow CY, King GF, Jain SK, Ordonez AA, Carroll LS, Reiner T, Pillarsetty N. Non-invasive diagnostic method to objectively measure olfaction and diagnose smell disorders by molecularly targeted fluorescent imaging agent. bioRxiv. 2022. Epub 20221129. doi: 10.1101/2021.10.07.463532. PubMed PMCID: PMC9727758;

Wilson T, Pirovano G, Xiao G, Samuels Z, Roberts S, Viray T, Guru N, Zanzonico P, Gollub M, Pillarsetty NVK, Reiner T, Bargonetti J. PARP-Targeted Auger Therapy in p53 Mutant Colon Cancer Xenograft Mouse Models. Mol Pharm. 2021;18(9):3418-28. Epub 20210728. doi: 10.1021/acs.molpharmaceut.1c00323. PubMed PMCID: PMC8686831;

Volpe A, Pillarsetty NVK, Lewis JS, Ponomarev V. Applications of nuclear-based imaging in gene and cell therapy: probe considerations. Mol Ther Oncolytics. 2021;20:447-58. Epub 20210204. doi: 10.1016/j.omto.2021.01.017. PubMed PMCID: PMC7907215;

Russell J, Grkovski M, O’Donoghue IJ, Kalidindi TM, Pillarsetty N, Burnazi EM, Kulick A, Bahr A, Chang Q, LeKaye HC, de Stanchina E, Yu KH, Humm JL. Predicting Gemcitabine Delivery by (18)F-FAC PET in Murine Models of Pancreatic Cancer. J Nucl Med. 2021;62(2):195-200. Epub 20200709. doi: 10.2967/jnumed.120.246926. PubMed PMCID: PMC9364871;

Pirovano G, Ordonez AA, Jain SK, Reiner T, Carroll LS, Pillarsetty NVK. Rapid detection of SARS-CoV-2 using a radiolabeled antibody. Nucl Med Biol. 2021;98-99:69-75. Epub 20210525. doi: 10.1016/j.nucmedbio.2021.05.002. PubMed PMCID: PMC8144098;

Pillarsetty N, Carter LM, Lewis JS, Reiner T. Reply: Potential Use of Radiolabeled Antibodies for Imaging and Treatment of COVID-19. J Nucl Med. 2021;62(7):1020-1. Epub 20210423. doi: 10.2967/jnumed.121.261950. PubMed PMCID: PMC8882887;

Nie P, Kalidindi T, Nagle VL, Wu X, Li T, Liao GP, Frost G, Henry KE, Punzalan B, Carter LM, Lewis JS, Pillarsetty NVK, Li YM. Imaging of Cancer gamma-Secretase Activity Using an Inhibitor-Based PET Probe. Clin Cancer Res. 2021;27(22):6145-55. Epub 20210902. doi: 10.1158/1078-0432.CCR-21-0940. PubMed PMCID: PMC8610083;

Kalidindi TM, Lee SG, Jou K, Chakraborty G, Skafida M, Tagawa ST, Bander NH, Schoder H, Bodei L, Pandit-Taskar N, Lewis JS, Larson SM, Osborne JR, Pillarsetty NVK. A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals. Eur J Nucl Med Mol Imaging. 2021;48(8):2642-51. Epub 20210125. doi: 10.1007/s00259-020-05150-w. PubMed PMCID: PMC10134681;

Joshi S, Gomes ED, Wang T, Corben A, Taldone T, Gandu S, Xu C, Sharma S, Buddaseth S, Yan P, Chan LYL, Gokce A, Rajasekhar VK, Shrestha L, Panchal P, Almodovar J, Digwal CS, Rodina A, Merugu S, Pillarsetty N, Miclea V, Peter RI, Wang W, Ginsberg SD, Tang L, Mattar M, de Stanchina E, Yu KH, Lowery M, Grbovic-Huezo O, O’Reilly EM, Janjigian Y, Healey JH, Jarnagin WR, Allen PJ, Sander C, Erdjument-Bromage H, Neubert TA, Leach SD, Chiosis G. Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer. Commun Biol. 2021;4(1):1333. Epub 20211125. doi: 10.1038/s42003-021-02842-3. PubMed PMCID: PMC8617294;

Henry KE, Mack KN, Nagle VL, Cornejo M, Michel AO, Fox IL, Davydova M, Dilling TR, Pillarsetty N, Lewis JS. ERK Inhibition Improves Anti-PD-L1 Immune Checkpoint Blockade in Preclinical Pancreatic Ductal Adenocarcinoma. Mol Cancer Ther. 2021;20(10):2026-34. Epub 20210804. doi: 10.1158/1535-7163.MCT-20-1112. PubMed PMCID: PMC8492510;

Harmsen S, Medine EI, Moroz M, Nurili F, Lobo J, Dong Y, Turkekul M, Pillarsetty NVK, Ting R, Ponomarev V, Akin O, Aras O. A dual-modal PET/near infrared fluorescent nanotag for long-term immune cell tracking. Biomaterials. 2021;269:120630. Epub 20201223. doi: 10.1016/j.biomaterials.2020.120630. PubMed PMCID: PMC7870530;

Bolaender A, Zatorska D, He H, Joshi S, Sharma S, Digwal CS, Patel HJ, Sun W, Imber BS, Ochiana SO, Patel MR, Shrestha L, Shah SK, Wang S, Karimov R, Tao H, Patel PD, Martin AR, Yan P, Panchal P, Almodovar J, Corben A, Rimner A, Ginsberg SD, Lyashchenko S, Burnazi E, Ku A, Kalidindi T, Lee SG, Grkovski M, Beattie BJ, Zanzonico P, Lewis JS, Larson S, Rodina A, Pillarsetty N, Tabar V, Dunphy MP, Taldone T, Shimizu F, Chiosis G. Chemical tools for epichaperome-mediated interactome dysfunctions of the central nervous system. Nat Commun. 2021;12(1):4669. Epub 20210803. doi: 10.1038/s41467-021-24821-2. PubMed PMCID: PMC8333062;

Wilson TC, Pillarsetty N, Reiner T. A one-pot radiosynthesis of [(18) F]PARPi. J Labelled Comp Radiopharm. 2020;63(9):419-25. Epub 20200616. doi: 10.1002/jlcr.3847. PubMed PMCID: PMC7551923;

Taldone T, Wang T, Rodina A, Pillarsetty NVK, Digwal CS, Sharma S, Yan P, Joshi S, Pagare PP, Bolaender A, Roboz GJ, Guzman ML, Chiosis G. A Chemical Biology Approach to the Chaperome in Cancer-HSP90 and Beyond. Cold Spring Harb Perspect Biol. 2020;12(4). Epub 20200401. doi: 10.1101/cshperspect.a034116. PubMed PMCID: PMC6773535;

Pratt EC, Isaac E, Stater EP, Yang G, Ouerfelli O, Pillarsetty N, Grimm J. Synthesis of the PET Tracer (124)I-Trametinib for MAPK/ERK Kinase Distribution and Resistance Monitoring. J Nucl Med. 2020;61(12):1845-50. Epub 20200522. doi: 10.2967/jnumed.120.241901. PubMed PMCID: PMC9364901;

Pillarsetty N, Carter LM, Lewis JS, Reiner T. Oncology-Inspired Treatment Options for COVID-19. J Nucl Med. 2020;61(12):1720-3. Epub 20200717. doi: 10.2967/jnumed.120.249748. PubMed PMCID: PMC8679628;

Jhaveri KL, Dos Anjos CH, Taldone T, Wang R, Comen E, Fornier M, Bromberg JF, Ma W, Patil S, Rodina A, Pillarsetty N, Duggan S, Khoshi S, Kadija N, Chiosis G, Dunphy MP, Modi S. Measuring Tumor Epichaperome Expression Using [(124)I] PU-H71 Positron Emission Tomography as a Biomarker of Response for PU-H71 Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast Cancer. JCO Precis Oncol. 2020;4. Epub 20201117. doi: 10.1200/PO.20.00273. PubMed PMCID: PMC7713524;

Inda MC, Joshi S, Wang T, Bolaender A, Gandu S, Koren Iii J, Che AY, Taldone T, Yan P, Sun W, Uddin M, Panchal P, Riolo M, Shah S, Barlas A, Xu K, Chan LYL, Gruzinova A, Kishinevsky S, Studer L, Fossati V, Noggle SA, White JR, de Stanchina E, Sequeira S, Anthoney KH, Steele JW, Manova-Todorova K, Patil S, Dunphy MP, Pillarsetty N, Pereira AC, Erdjument-Bromage H, Neubert TA, Rodina A, Ginsberg SD, De Marco Garcia N, Luo W, Chiosis G. The epichaperome is a mediator of toxic hippocampal stress and leads to protein connectivity-based dysfunction. Nat Commun. 2020;11(1):319. Epub 20200116. doi: 10.1038/s41467-019-14082-5. PubMed PMCID: PMC6965647;

Gangangari KK, Varadi A, Majumdar S, Larson SM, Pasternak GW, Pillarsetty NK. Imaging Sigma-1 Receptor (S1R) Expression Using Iodine-124-Labeled 1-(4-Iodophenyl)-3-(2-adamantyl)guanidine ([(124)I]IPAG). Mol Imaging Biol. 2020;22(2):358-66. doi: 10.1007/s11307-019-01369-8. PubMed PMCID: PMC6893110;

Fanchon LM, Russell J, Pillarsetty N, O’Donoghue I, Gangangari K, Yu KH, Humm JL. Comparing the intra-tumoral distribution of Gemcitabine, 5-Fluorouracil, and Capecitabine in a murine model of pancreatic ductal adenocarcinoma. PLoS One. 2020;15(4):e0231745. Epub 20200416. doi: 10.1371/journal.pone.0231745. PubMed PMCID: PMC7162455;

Dunphy MPS, Pressl C, Pillarsetty N, Grkovski M, Modi S, Jhaveri K, Norton L, Beattie BJ, Zanzonico PB, Zatorska D, Taldone T, Ochiana SO, Uddin MM, Burnazi EM, Lyashchenko SK, Hudis CA, Bromberg J, Schoder HM, Fox JJ, Zhang H, Chiosis G, Lewis JS, Larson SM. First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer. Clin Cancer Res. 2020;26(19):5178-87. Epub 20200504. doi: 10.1158/1078-0432.CCR-19-3704. PubMed PMCID: PMC7541604;

Dunphy MPS, Pillarsetty N. The Unique Pharmacometrics of Small Molecule Therapeutic Drug Tracer Imaging for Clinical Oncology. Cancers (Basel). 2020;12(9). Epub 20200922. doi: 10.3390/cancers12092712. PubMed PMCID: PMC7563483;

Cheal SM, McDevitt MR, Santich BH, Patel M, Yang G, Fung EK, Veach DR, Bell M, Ahad A, Vargas DB, Punzalan B, Pillarsetty NVK, Xu H, Guo HF, Monette S, Michel AO, Piersigilli A, Scheinberg DA, Ouerfelli O, Cheung NV, Larson SM. Alpha radioimmunotherapy using (225)Ac-proteus-DOTA for solid tumors - safety at curative doses. Theranostics. 2020;10(25):11359-75. Epub 20200914. doi: 10.7150/thno.48810. PubMed PMCID: PMC7546012;

Sharma SK, Lyashchenko SK, Park HA, Pillarsetty N, Roux Y, Wu J, Poty S, Tully KM, Poirier JT, Lewis JS. A rapid bead-based radioligand binding assay for the determination of target-binding fraction and quality control of radiopharmaceuticals. Nucl Med Biol. 2019;71:32-8. Epub 20190503. doi: 10.1016/j.nucmedbio.2019.04.005. PubMed PMCID: PMC6599726;

Pillarsetty N, Jhaveri K, Taldone T, Caldas-Lopes E, Punzalan B, Joshi S, Bolaender A, Uddin MM, Rodina A, Yan P, Ku A, Ku T, Shah SK, Lyashchenko S, Burnazi E, Wang T, Lecomte N, Janjigian Y, Younes A, Batlevi CW, Guzman ML, Roboz GJ, Koziorowski J, Zanzonico P, Alpaugh ML, Corben A, Modi S, Norton L, Larson SM, Lewis JS, Chiosis G, Gerecitano JF, Dunphy MPS. Paradigms for Precision Medicine in Epichaperome Cancer Therapy. Cancer Cell. 2019;36(5):559-73 e7. Epub 20191024. doi: 10.1016/j.ccell.2019.09.007. PubMed PMCID: PMC6996250;